8HLT
 
 | | The co-crystal structure of DYRK2 with YK-2-99B | | 分子名称: | (6-{[(4P)-4-(1,3-benzothiazol-5-yl)-5-fluoropyrimidin-2-yl]amino}pyridin-3-yl)(piperazin-1-yl)methanone, Dual specificity tyrosine-phosphorylation-regulated kinase 2 | | 著者 | Shen, H.T, Xiao, Y.B, Yuan, K, Yang, P, Li, Q.N. | | 登録日 | 2022-12-01 | | 公開日 | 2023-12-13 | | 実験手法 | X-RAY DIFFRACTION (2.8 Å) | | 主引用文献 | Discovery of Potent DYRK2 Inhibitors with High Selectivity, Great Solubility, and Excellent Safety Properties for the Treatment of Prostate Cancer.
J.Med.Chem., 66, 2023
|
|
8HVA
 | |
8HV2
 | |
8HV9
 | | Crystal structure of EGFR_TMX in complex with covalently bound fragment 12 | | 分子名称: | 3,6,9,12,15,18,21,24-OCTAOXAHEXACOSAN-1-OL, DIMETHYL SULFOXIDE, Epidermal growth factor receptor, ... | | 著者 | Dokurno, P. | | 登録日 | 2022-12-26 | | 公開日 | 2023-12-13 | | 最終更新日 | 2024-04-03 | | 実験手法 | X-RAY DIFFRACTION (2.5 Å) | | 主引用文献 | A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase.
Rsc Med Chem, 14, 2023
|
|
8HV1
 | | Crystal structure of EGFR_DMX in complex with covalently bound fragment 1 | | 分子名称: | 3,6,9,12,15,18,21,24-OCTAOXAHEXACOSAN-1-OL, 3-(3-bromophenyl)-1,4-dihydro-1,2,4-triazole-5-thione, Epidermal growth factor receptor, ... | | 著者 | Dokurno, P. | | 登録日 | 2022-12-26 | | 公開日 | 2023-12-13 | | 最終更新日 | 2024-04-03 | | 実験手法 | X-RAY DIFFRACTION (2.4 Å) | | 主引用文献 | A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase.
Rsc Med Chem, 14, 2023
|
|
8HV5
 | | Crystal structure of EGFR_DMX in complex with compound 7 | | 分子名称: | 3,6,9,12,15,18,21,24-OCTAOXAHEXACOSAN-1-OL, Epidermal growth factor receptor, ~{N}-(1-methylbenzimidazol-4-yl)prop-2-enamide | | 著者 | Dokurno, P. | | 登録日 | 2022-12-26 | | 公開日 | 2023-12-13 | | 最終更新日 | 2024-04-03 | | 実験手法 | X-RAY DIFFRACTION (2.2 Å) | | 主引用文献 | A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase.
Rsc Med Chem, 14, 2023
|
|
8HV6
 | | Crystal structure of EGFR_TMX in complex with covalently bound fragment 8 | | 分子名称: | 3,6,9,12,15,18,21,24-OCTAOXAHEXACOSAN-1-OL, DIMETHYL SULFOXIDE, Epidermal growth factor receptor, ... | | 著者 | Dokurno, P. | | 登録日 | 2022-12-26 | | 公開日 | 2023-12-13 | | 最終更新日 | 2024-04-03 | | 実験手法 | X-RAY DIFFRACTION (2.2 Å) | | 主引用文献 | A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase.
Rsc Med Chem, 14, 2023
|
|
8HV3
 | | Crystal structure of EGFR_DMX in complex with covalently bound fragment 4 | | 分子名称: | 3,6,9,12,15,18,21,24-OCTAOXAHEXACOSAN-1-OL, DIMETHYL SULFOXIDE, Epidermal growth factor receptor, ... | | 著者 | Dokurno, P. | | 登録日 | 2022-12-26 | | 公開日 | 2023-12-13 | | 最終更新日 | 2024-04-03 | | 実験手法 | X-RAY DIFFRACTION (2.4 Å) | | 主引用文献 | A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase.
Rsc Med Chem, 14, 2023
|
|
8HV8
 | | Crystal structure of EGFR_TMX in complex with covalently bound fragment 10 | | 分子名称: | 3,6,9,12,15,18,21,24-OCTAOXAHEXACOSAN-1-OL, Epidermal growth factor receptor, ~{N}-pyrazolo[1,5-a]pyridin-2-ylprop-2-enamide | | 著者 | Dokurno, P. | | 登録日 | 2022-12-26 | | 公開日 | 2023-12-13 | | 最終更新日 | 2024-04-03 | | 実験手法 | X-RAY DIFFRACTION (2.4 Å) | | 主引用文献 | A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase.
Rsc Med Chem, 14, 2023
|
|
8HV4
 | | Crystal structure of EGFR_TMX in complex with covalently bound fragment 4 | | 分子名称: | 3,6,9,12,15,18,21,24-OCTAOXAHEXACOSAN-1-OL, CHLORIDE ION, DIMETHYL SULFOXIDE, ... | | 著者 | Dokurno, P. | | 登録日 | 2022-12-26 | | 公開日 | 2023-12-13 | | 最終更新日 | 2024-04-03 | | 実験手法 | X-RAY DIFFRACTION (2.2 Å) | | 主引用文献 | A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase.
Rsc Med Chem, 14, 2023
|
|
8HV7
 | | Crystal structure of EGFR_TMX in complex with covalently bound fragment 9 | | 分子名称: | 3,6,9,12,15,18,21,24-OCTAOXAHEXACOSAN-1-OL, DIMETHYL SULFOXIDE, Epidermal growth factor receptor, ... | | 著者 | Dokurno, P. | | 登録日 | 2022-12-26 | | 公開日 | 2023-12-13 | | 最終更新日 | 2024-04-03 | | 実験手法 | X-RAY DIFFRACTION (2.69 Å) | | 主引用文献 | A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase.
Rsc Med Chem, 14, 2023
|
|
8HTS
 | | Crystal structure of Bcl2 in complex with S-10r | | 分子名称: | 4-[2-[(2~{S})-2-(2-cyclopropylphenyl)pyrrolidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]-~{N}-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1~{H}-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide, Apoptosis regulator Bcl-2 | | 著者 | Liu, J, Xu, M, Feng, Y, Liu, Y. | | 登録日 | 2022-12-21 | | 公開日 | 2024-05-15 | | 最終更新日 | 2024-06-05 | | 実験手法 | X-RAY DIFFRACTION (1.25 Å) | | 主引用文献 | Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2.
J.Med.Chem., 67, 2024
|
|
8IJS
 | | anti-VEGF nanobody mutant | | 分子名称: | ZINC ION, anti-VEGF nanobody | | 著者 | Qian, F, Zhu, S.Q. | | 登録日 | 2023-02-28 | | 公開日 | 2023-12-27 | | 実験手法 | X-RAY DIFFRACTION (1.752 Å) | | 主引用文献 | Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration.
Bioeng Transl Med, 8, 2023
|
|
8IIU
 | | anti-VEGF nanobody | | 分子名称: | SULFATE ION, anti-VEGF nanobody | | 著者 | Qian, F, Zhu, S.Q. | | 登録日 | 2023-02-24 | | 公開日 | 2023-12-27 | | 実験手法 | X-RAY DIFFRACTION (1.27 Å) | | 主引用文献 | Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration.
Bioeng Transl Med, 8, 2023
|
|
8IJZ
 | | anti-VEGF mutant | | 分子名称: | anti-VEGF nanobody | | 著者 | Qian, F, Zhu, S.Q. | | 登録日 | 2023-02-28 | | 公開日 | 2023-12-27 | | 実験手法 | ELECTRON CRYSTALLOGRAPHY (2.1 Å) | | 主引用文献 | Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration.
Bioeng Transl Med, 8, 2023
|
|
8II1
 | | Crystal structure of V30M-TTR in complex with BID | | 分子名称: | Benziodarone, Transthyretin | | 著者 | Yokoyama, T. | | 登録日 | 2023-02-24 | | 公開日 | 2023-06-28 | | 最終更新日 | 2023-11-08 | | 実験手法 | X-RAY DIFFRACTION (1.907 Å) | | 主引用文献 | Benziodarone and 6-hydroxybenziodarone are potent and selective inhibitors of transthyretin amyloidogenesis.
Bioorg.Med.Chem., 90, 2023
|
|
8II4
 | | Crystal structure of V30M-TTR in complex with 6-hydroxy BBM | | 分子名称: | Transthyretin, [3,5-bis(bromanyl)-4-oxidanyl-phenyl]-(2-ethyl-6-oxidanyl-1-benzofuran-3-yl)methanone | | 著者 | Yokoyama, T. | | 登録日 | 2023-02-24 | | 公開日 | 2023-06-28 | | 最終更新日 | 2024-05-29 | | 実験手法 | X-RAY DIFFRACTION (1.499 Å) | | 主引用文献 | Benziodarone and 6-hydroxybenziodarone are potent and selective inhibitors of transthyretin amyloidogenesis.
Bioorg.Med.Chem., 90, 2023
|
|
8II3
 | | Crystal structure of V30M-TTR in complex with 6-hydroxy BID | | 分子名称: | Transthyretin, [3,5-bis(iodanyl)-4-oxidanyl-phenyl]-(2-ethyl-6-oxidanyl-1-benzofuran-3-yl)methanone | | 著者 | Yokoyama, T. | | 登録日 | 2023-02-24 | | 公開日 | 2023-06-28 | | 最終更新日 | 2024-05-29 | | 実験手法 | X-RAY DIFFRACTION (1.399 Å) | | 主引用文献 | Benziodarone and 6-hydroxybenziodarone are potent and selective inhibitors of transthyretin amyloidogenesis.
Bioorg.Med.Chem., 90, 2023
|
|
8II2
 | | Crystal structure of V30M-TTR in complex with BBM | | 分子名称: | CALCIUM ION, Transthyretin, [3,5-bis(bromanyl)-4-oxidanyl-phenyl]-(2-ethyl-1-benzofuran-3-yl)methanone | | 著者 | Yokoyama, T. | | 登録日 | 2023-02-24 | | 公開日 | 2023-06-28 | | 最終更新日 | 2024-05-29 | | 実験手法 | X-RAY DIFFRACTION (1.798 Å) | | 主引用文献 | Benziodarone and 6-hydroxybenziodarone are potent and selective inhibitors of transthyretin amyloidogenesis.
Bioorg.Med.Chem., 90, 2023
|
|
8I71
 | | Hepatitis B virus core protein Y132A mutant in complex with Linvencorvir (RG7907), a Hepatitis B Virus (HBV) Core Protein Allosteric Modulator (CpAM) | | 分子名称: | 3-[(8~{a}~{S})-7-[[5-ethoxycarbonyl-4-(3-fluoranyl-2-methyl-phenyl)-2-(1,3-thiazol-2-yl)-1,4-dihydropyrimidin-6-yl]methyl]-3-oxidanylidene-5,6,8,8~{a}-tetrahydro-1~{H}-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimethyl-propanoic acid, CHLORIDE ION, Capsid protein, ... | | 著者 | Zhou, Z, Xu, Z.H. | | 登録日 | 2023-01-30 | | 公開日 | 2023-03-22 | | 最終更新日 | 2023-04-05 | | 実験手法 | X-RAY DIFFRACTION (1.6 Å) | | 主引用文献 | Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection.
J.Med.Chem., 66, 2023
|
|
8IVR
 | | Methyl and Fluorine Effects in Novel Orally Bioavailable Keap1/Nrf2 PPI Inhibitor for Treatment of Chronic Kidney Disease | | 分子名称: | (2R,3S)-2-methyl-3-(4-methylphenyl)-3-[2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethanoylamino]propanoic acid, Kelch-like ECH-associated protein 1, SULFATE ION | | 著者 | Nomura, A, Yamaguchi, K, Adachi, T. | | 登録日 | 2023-03-28 | | 公開日 | 2023-06-14 | | 最終更新日 | 2024-05-29 | | 実験手法 | X-RAY DIFFRACTION (1.5 Å) | | 主引用文献 | Methyl and Fluorine Effects in Novel Orally Bioavailable Keap1-Nrf2 PPI Inhibitor.
Acs Med.Chem.Lett., 14, 2023
|
|
8IVG
 | | Methyl and Fluorine Effects in Novel Orally Bioavailable Keap1/Nrf2 PPI Inhibitor for Treatment of Chronic Kidney Disease | | 分子名称: | (3S)-3-(4-methylphenyl)-3-[2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethanoylamino]propanoic acid, 2,3-DIHYDROXY-1,4-DITHIOBUTANE, Kelch-like ECH-associated protein 1, ... | | 著者 | Otake, K, Ubukata, M, Nagahashi, N, Ogawa, N, Hantani, Y, Hantani, R, Adachi, T, Nomura, A, Yamaguchi, K, Maekawa, M, Mamada, H, Motomura, T, Sato, M, Harada, K. | | 登録日 | 2023-03-27 | | 公開日 | 2023-06-14 | | 最終更新日 | 2024-05-29 | | 実験手法 | X-RAY DIFFRACTION (1.8 Å) | | 主引用文献 | Methyl and Fluorine Effects in Novel Orally Bioavailable Keap1-Nrf2 PPI Inhibitor.
Acs Med.Chem.Lett., 14, 2023
|
|
8I67
 | | Crystal structure of Mycobacterium tuberculosis Uracil-DNA glycosylase in complex with 2,4-Thiazolidinedione, Form I | | 分子名称: | 1,2-ETHANEDIOL, 1,3-thiazolidine-2,4-dione, Uracil-DNA glycosylase | | 著者 | Raj, P, Paul, A, Gopal, B. | | 登録日 | 2023-01-27 | | 公開日 | 2023-07-12 | | 最終更新日 | 2024-05-08 | | 実験手法 | X-RAY DIFFRACTION (1.72 Å) | | 主引用文献 | Crystal structures of non-uracil ring fragments in complex with Mycobacterium tuberculosis uracil DNA glycosylase (MtUng) as a starting point for novel inhibitor design: A case study with the barbituric acid fragment.
Eur.J.Med.Chem., 258, 2023
|
|
8IVW
 | | Crystal structure of NRP2 in complex with aNRP2-10 Fab fragment | | 分子名称: | Heavy chian of antibody 10V8 Fab fragment, Light chain of antibody 10V8 Fab fragment, Neuropilin-2 | | 著者 | Geng, Y, Zhai, L. | | 登録日 | 2023-03-29 | | 公開日 | 2023-07-12 | | 最終更新日 | 2023-08-23 | | 実験手法 | X-RAY DIFFRACTION (3.205 Å) | | 主引用文献 | Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer.
Sci Transl Med, 15, 2023
|
|
8I63
 | | Crystal structure of Mycobacterium tuberculosis Uracil-DNA glycosylase in complex with Barbituric acid, Form III | | 分子名称: | 1,2-ETHANEDIOL, BARBITURIC ACID, Uracil-DNA glycosylase | | 著者 | Raj, P, Paul, A, Gopal, B. | | 登録日 | 2023-01-27 | | 公開日 | 2023-07-12 | | 最終更新日 | 2024-05-08 | | 実験手法 | X-RAY DIFFRACTION (1.95 Å) | | 主引用文献 | Crystal structures of non-uracil ring fragments in complex with Mycobacterium tuberculosis uracil DNA glycosylase (MtUng) as a starting point for novel inhibitor design: A case study with the barbituric acid fragment.
Eur.J.Med.Chem., 258, 2023
|
|
